The Top 5 Analyst Questions From ANI Pharmaceuticals's Q1 Earnings Call [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
Management attributed the quarter's revenue strength to a surge in generics sales, ongoing robust demand for Cortrophin Gel, and increased activity in branded products. CEO Nikhil Lalwani said, “The first quarter reflected particularly strong performance for our generics business, continued solid demand for Cortrophin Gel, and increased demand for our brands portfolio.” However, margin pressures and near-term challenges in the retina segment weighed on investor sentiment. Is now the time to buy ANIP? Find out in our full research report (it's free). Revenue: $197.1 million vs analyst estimates of $179.6 million (43.4% year-on-year growth, 9.8% beat) Adjusted EPS: $1.70 vs analyst estimates of $1.38 (23% beat) Adjusted EBITDA: $50.75 million vs analyst estimates of $42.4 million (25.7% margin, 19.7% beat) The company lifted its revenue guidance for the full year to $780.5 million at the midpoint from $766 million, a 1.9% increase Management raised its full-year Adjusted EPS
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally [Yahoo! Finance]Yahoo! Finance
- Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? [Yahoo! Finance]Yahoo! Finance
- How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council [Yahoo! Finance]Yahoo! Finance
- Implied Volatility Surging for ANI Pharmaceuticals Stock Options [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals (NASDAQ:ANIP) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $100.00 price target on the stock.MarketBeat
ANIP
Earnings
- 11/7/25 - Beat
ANIP
Sec Filings
- 12/19/25 - Form 4
- 12/12/25 - Form 4
- 12/9/25 - Form 4
- ANIP's page on the SEC website